RT Book, Section A1 Costner, Melissa I. A1 Sontheimer, Richard D. A2 Goldsmith, Lowell A. A2 Katz, Stephen I. A2 Gilchrest, Barbara A. A2 Paller, Amy S. A2 Leffell, David J. A2 Wolff, Klaus SR Print(0) ID 56075741 T1 Chapter 155. Lupus Erythematosus T2 Fitzpatrick's Dermatology in General Medicine, 8e YR 2012 FD 2012 PB The McGraw-Hill Companies PP New York, NY SN 978-0-07-166904-7 LK accessmedicine.mhmedical.com/content.aspx?aid=56075741 RD 2024/04/23 AB |PrintLupus at a GlanceA group of heterogeneous illnesses that have in common the development of immunity to self-nucleic acids and their associated proteins, with skin-only disease at one end of the spectrum and severe visceral involvement at the other.Skin lesions may be specific to lupus or nonspecific and are seen in other conditions as well.Acute cutaneous lupus erythematosus (malar rash) is almost always associated with underlying visceral involvement, subacute cutaneous lupus patients meet systemic lupus erythematosus criteria about 50% of the time (but typically express only mild systemic clinical manifestations), and chronic cutaneous lupus (discoid lupus erythematosus, lupus panniculitis, chilblain lupus, and tumid lupus erythematosus) patients most often have skin-only or skin-predominant disease.Discoid lupus erythematosus causes scarring and can be permanently disfiguring. Subacute cutaneous lupus and acute cutaneous lupus erythematosus are highly photosensitive and are characteristically nonscarring.Lupus erythematosus-nonspecific skin lesions include nonscarring alopecia, mouth ulcers, photosensitivity, Raynaud's phenomenon, and vasculitis/vasculopathy, among others. They often herald a systemic lupus erythematosus flare.Treatment consists of sunscreens, local and systemic (short-term) glucocorticoids, antimalarials, retinoids, immunosuppressives, thalidomide, and biologic therapies.Lupus erythematosus occurs much more commonly in women (9:1 female-male ratio).Both systemic lupus erythematosus and cutaneous lupus erythematosus are associated with upregulation of class I interferon signaling.